Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Appointment of Greg Smith as CEO of Endomines AB (publ)

Endomines AB, Stock Exchange Release 6 November 2019, at 15:00 CET Endomines is pleased to announce that it has today appointed Greg Smith as Chief Executive Officer of the company. Greg has, on a consultancy basis, been leading Endomines’ operations in the US and Finland since June 5[th ]2019, when Endomines communicated that it was evaluating the appointment of Greg as CEO of Endomines. Greg Smith will assume the position of CEO as soon as he has been granted a Swedish work permit (Sw. ICT-tillstånd), which is expected to be granted in February 2020, by the latest. Greg Smith has a

Neonode Reports Third Quarter Ended September 30, 2019 Financial Results

STOCKHOLM, SWEDEN – November 6, 2019 – Neonode Inc. (NASDAQ: NEON), the optical interactive sensing technology company, today reported financial results for the three and nine months ended September 30, 2019.”There is significant interest for Neonode’s sensor and license technology in the automotive and other key markets but in our business, we have to accept long lead times in acquiring new customer contracts. Having said that, we are not satisfied with the development over the last 12-18 months. Our newly recruited CEO, Dr. Urban Forssell, brings a deep understanding of the automotive

Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019

STOCKHOLM — November 6, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma and Light Chain (AL) Amyloidosis have been selected for six poster presentations to be featured at the American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10 in Orlando, Florida. Melflufen is a peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC).A wide range of clinical and preclinical data for melflufen in both multiple myeloma and AL

Notice from bondholders' meeting DOF Subsea AS

Reference is made to the summons to a bondholders' meeting in DOFSUB07 (ISIN NO 001 0670144) issued on 22 October 2019. The bondholders' meeting was held today, and the proposed resolution was approved by 100% of the votes in cast at the bondholders' meeting. The bond agreement for DOFSUB07 will therefore be changed as set out in the summons. The minutes from the bondholders' meeting is attached. For further information, please contact: CEO Mons Aase, tel. +47 91 66 10 12 CFO Hilde Drønen, tel. +47 91 66 10 09

Updates from Keliber Oy

Today, Keliber Oy (“Keliber”) announced the extraordinary general meeting’s appointment of Mr. Mika Seitovirta (M.Sc.Econ) as the new Chairman of the Board of Directors. In a separate notice Keliber also provided a project update, including the identification of certain factors that need to be further assessed and planned, which impacts the project timeline. Due to the changes in end product and production process, additional technical and environmental planning has been required. Keliber has also evaluated the length of the upcoming construction and updated the construction master

Mika Seitovirta has been appointed as a Chairman of the Board of Keliber Oy

Keliber Oy's Extraordinary General Meeting held on November 6, 2019 appointed Mr. Mika Seitovirta (M.Sc. Econ) as the new Chairman of the Board of Directors. Seitovirta has extensive international experience in managing global companies. He has previously served as CEO of Outokumpu Oyj, Glaston Corporation and Hartwall / Scottish & Newcastle, among others. Currently, Seitovirta works as an advisor and a Board professional in Finland and internationally. "I am proud and excited to be part of developing Keliber’s lithium project towards construction and production phase. The company's

Transfer of EAB Group’s own shares

EAB Group Plc, Stock Exchange Release, 6 November 2019, 3:30 p.m. (EET) Transfer of EAB Group’s own shares On 6 November 2019, EAB Group Plc transferred a total of 3,247 own shares held by the company to the key employees of the company without consideration. The transfer is related to the payment of deferred variable remuneration and is in accordance with the Company's remuneration scheme. The regulation requires that, to the extent that a reward scheme for so-called risk-takers may result in a variable remuneration of more than €50,000 per calendar year, at least 40% of the

Orkla ASA: Issuance of Commercial Paper

Orkla ASA has issued a commercial paper of NOK 300,000,000. Start date:                  11 November 2019Maturity:                     11 December 2019Coupon:                     1.73 %Organised by:             Handelsbanken Markets       Orkla ASAOslo, 6 November 2019 Ref.: Senior Vice President Group TreasuryGeir SolliTel.: +47 995 42 789 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting

Lund, Sweden, November 6, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinical data showing that their drug candidate ATOR-1017 can induce a long-lasting immunological memory which is of great importance in a potential future patient setting. The results will be presented at the ongoing Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. The ATOR-1017 drug candidate is in development for the treatment of metastasized cancer. Furthermore, the results show that treatment with ATOR-1017 activates the immune system

Saab’s New Electronic Attack Jammer Pod in the Air

Saab carried out the first flight tests with its new advanced Electronic Attack Jammer Pod (EAJP) with successful results on 4 November 2019. The pod’s interfaces with the aircraft’s hardware and software as well as cockpit control and monitoring were tested during the flight.The purpose of Saab’s new EAJP pod is to protect aircraft against radars by sophisticated jamming functions, thereby blocking the opponent’s ability to attack them. The first flight marks an important step of the pod’s development programme. Saab is sharpening its electronic attack capabilities and the new advanced

STRAX: URBANISTA CONTINUES TO DELIVER

Urbanista, the lifestyle audio brand owned by STRAX, continues its path towards a record year in 2019.Following the success of the true wireless headphones Stockholm which remains one of the fundamental products in the Urbanista product portfolio, Urbanista has this fall launched two additional true wireless headphones – Paris and Athens – as well as two true wireless speakers – Sydney and Brisbane – all addressing the true wireless opportunity, the fast growing market segment of the global audio industry. During the year Urbanista has entered into several important collaborations, for

InCoax Networks AB (publ) announces the results of the rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.The subscription period for the new share issue in InCoax Networks AB (publ) (“InCoax” or the “Company”) with preferential rights for existing shareholders (the “Rights Issue”) was completed on November 1, 2019. The outcome of the Rights Issue, which was covered by subscription and guarantee commitments corresponding to 80

TrustShield™, Ahlstrom-Munksjö’s single-use medical fabrics for ultimate protection in the operating room, clinical environment and laboratory

AHLSTROM-MUNKSJÖ, PRESS RELEASE, NOVEMBER 6, 2019 at 2:30 P.M. EET Ahlstrom-Munksjö announces the launch of TrustShield™, a versatile portfolio of medical fabrics that can be used to provide protection against surgical lasers, chemicals and potent chemotherapy drugs. TrustShield™ products were specially designed around growing market trends. The evolution of laser technology in a surgical environment has significantly advanced as their usage has become widespread for numerous specialties. Although there are many benefits to using lasers for surgical procedures, there are also risks.

Invitation to 3Q 2019 presentation

Otello Corporation ASA is presenting its 3Q 2019 results on Wednesday, November 13, 2019, at 08:00am CET. The presentation will take place at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. A live webcast will be available at: https://otellocorp.com/ir   Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@otellocorp.com   About Otello: Otello holds shares in several different businesses, including (i)AdColony which helps publishers monetize their content through advertising and advertisers reach the audiences that build value for their businesses, capitalizing on

TOMRA: SUCCESSFUL ISSUANCE OF UNSECURED BONDS

Reference is made to the Q3-presentation and announcement dated 21 October 2019 regarding contemplated bond issue. TOMRA Systems ASA has today successfully issued a total amount of NOK 1,000m in senior unsecured bonds. The transaction is split in two tranches, both were significantly oversubscribed: - 3Y FRN: NOK 400m with a coupon of 3m Nibor + 0.50 % p.a. - 5Y FRN: NOK 600m with a coupon of 3m Nibor + 0.75 % p.a. The net proceeds will be used for general corporate purposes, including refinancing of existing debt. The settlement date is 14 November 2019 and the bonds will be

Kindred - winner of Sweden´s Best Looking Office

Kindred Group is the proud winner of ‘Sweden´s Best Looking Office’. The competition puts the spotlight on companies that have successfully combined aesthetic and compelling environments with a smart and flexible working space adapted to fit the organisations specific needs. Kindred Group moved into its award-winning, purpose-built facility in April this year.Kindred Group (former Unibet Group) is the proud winner of Sweden´s Best Looking Office. A competition arranged annually by Fastighetssverige and Lokalnytt.se.  Kindred moved into their new office at Urban Escape in central Stockholm

Dicot signs Agreement for Contract Research with Pelvipharm

November 6, 2019, Uppsala, Sweden – Dicot AB (publ) (“Dicot” or the “Company”) announced today that the company has entered into a research collaboration agreement with Pelvipharm, a world-leading contract research organization (CRO) based in France. This research collaboration is focused on the identification of Libiguin’s® mechanisms of action, which is a key step towards defining the exact domain for clinical use of the drug, and to support its registration as an approved drug. Pelvipharm specializes in the field of male and female sexual dysfunctions, offering both in vivo and in

Nexam Chemical presents the third quarter for 2019 on November 12 th at 11:00 CET

Nexam Chemical will publish the interim report for the third quarter 2019 on November 12th, 2019 at 08:30 CET. The report and the presentation  will be available at the company website.In connection with the release - analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Johan Arvidsson, CEO will present and comment the report. The presentation will be held in Swedish via a conference call or audio webcast at https://financialhearings.com/event/11856. If you do not intend

Peab renovates and extends school in Norway

Eikeli High School in Bærum, Norway is going to be renovated and extended. Peab has been commissioned to do the work by AFK eiendom FKF and the contract is worth NOK 193 million.Peab is going to renovate around 2,100 m2 of the existing school that was built in 1960. As part of the contract Peab will also build a new 4,500 m2 school building. “Peab has invested a great deal in public projects concerning care, health, schools and education. This project is a result of our initiative and we will be building up vital experience for future projects like this one,” says Trond Ormstad, Region

Metsä Board Corporation: Managers’ transactions

Metsä Board Corporation Managers’ transactions 6 November 2019 at 12 noon EETMetsäliitto Cooperative, which is a closely associated party to Metsä Board’s chairman and two members of the Board, has acquired on 1 November Metsä Board Corporation’s B shares. Metsä Board Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Metsäliitto Osuuskunta Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Hämälä Ilkka Position: Member

Cimco Marine AB (publ) has completed directed share issue of SEK 17,2 million

The directed share issue in Cimco Marine AB (publ) (“Cimco”) resolved by the board of directors on 24 October 2019, as authorized by the annual general meeting on 14 May 2019, has been fully subscribed. A total of 11,451,369 shares have been subscribed for by the guarantee consortium that entered into guarantee commitments in connection with the exercise period for the warrants of series 2019:1. Through the directed share issue, Cimco receives approximately SEK 17,2 million.The new shares were issued at a subscription price of SEK 1.50 per share. The subscription price for the new shares is

NORDEN initiates share buy-back programme

ANNOUNCEMENT NO. 17 - 6 NOVEMBER 2019 The Board of Directors has decided to carry out a share buy-back of up to a total of USD 10 million (approximately DKK 67 million). The share buy-back programme is initiated pursuant to the authorisation granted to the Board of Directors, which entitles NORDEN to acquire treasury shares at a nominal value not exceeding 10% of the share capital at the market price applicable at the time of acquisition with a deviation of up to 10%. This authorisation was most recently renewed at NORDEN’s general meeting on 11 April 2019. PurposeThe purpose of the

IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe

IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities. The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies. Securing the intellectual property rights is an important step in protecting the results of the company’s research and strengthens the projects’ position and commercial potential.Drug candidates IRL942 and IRL1009 stem from IRLAB’s P001 research program and are

There are no items matching the current filter
There are no more items matching the current filter
Back to top